Our team

Peter Fong, PhD

Partner, President

Peter is a partner and the president of RTW. In addition to his broad management and oversight of the firm, Peter has retained his role as head of Asset Development and Financing (ADF). One of ADF’s primary responsibilities is the creation and incubation of RTW-founded companies.

Peter also serves as founding CEO and board member of RTW’s incubated companies, building their management teams, pipelines, and drug development capabilities with the goal of creating the next generation of leading biotech firms capable of bringing life-saving medicines to patients. He currently serves on the board of directors for both Ji Xing Pharmaceuticals and Yarrow Biotechnologies, which were founded by RTW under his leadership.

Prior to joining RTW, Peter worked at Flagship Pioneering in Cambridge as a member of the innovation team. In this role he led the creation of four Flagship companies, including Harbinger Health, and served as the founding CEO of each of them.

Biotech entrepreneurism is central to the unprecedented biological innovation revolutionizing medicine. It’s a thrill to come to the office each day and work with colleagues as talented and entrepreneurial as they are at RTW. Together, we seek to create world class biotech companies – from the ground up – capable of taking on the worst diseases.

Peter previously worked at Genentech in Business Development, where he helped build the company’s pipeline through partnering. Peter led multiple transactions for Genentech, including the company’s collaboration with BioNTech to develop mRNA-based personalized cancer vaccines. He has also worked at Memorial Sloan-Kettering; Carigent Therapeutics, which he co-founded; and General Electric as a chemist.

Peter received a PhD in bioengineering from Yale University, where he subsequently was a Brown-Coxe Postdoctoral Fellow, and his BS in biochemistry from Indiana University.

Share profile

Back to our team

This website is not intended to offer or to promote the offer or sale of the shares (the “Shares”) of RTW Biotech Opportunities Ltd (the “Company”) in the United States or to any “U.S. persons” as defined in Regulation S (“US persons”) under the US Securities Act of 1933, as amended (the “Securities Act”). The materials contained herein are not for release, publication or distribution, directly or indirectly, in whole or in part, to any persons to whom or into or within any jurisdiction where to do so would constitute a violation of applicable law or regulation.

The information contained herein and on the pages that follow does not constitute or form a part of any offer to sell or issue, or the solicitation of any offer to purchase, subscribe for or otherwise acquire, any securities in the United States or in any jurisdiction in which, or to any person to whom, such an offer or solicitation would be unlawful.

The Company has not been and will not be registered under the US Investment Company Act of 1940, as amended (the “Investment Company Act”), and as such holders of the Shares are not and will not be entitled to the benefits of the Investment Company Act. The Shares have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, pledged, delivered, assigned or otherwise transferred, directly or indirectly, into or within the United States or to, or for the account or benefit of, any US Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States and in a manner which would not result in the Company being required to register under the Investment Company Act. There has been and will be no public offer of the Shares in the United States. The offer and sale of the Shares have not been and will not be registered under the applicable securities laws of Australia, Canada, Japan or South Africa. Potential users of the information contained herein and on the pages that follow are requested to inform themselves about and to observe all applicable restrictions.

The information contained herein and on the pages that follow may contain forward-looking statements. Any statement other than a statement of historical fact is a forward-looking statement. Actual results may differ materially from those expressed or implied by any forward-looking statement. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. You should not place undue reliance on any forward-looking statement, which speaks only as of the date of its issuance. The Company may change these terms and conditions from time to time and any such changes will be posted on this website. Your access to this website is governed by the version of these terms and conditions then in force.

By clicking “Agree” below, you represent, warrant, undertake and agree that (1) you have read, understood and agree to be bound by the terms and conditions and other information set out herein, (2) you are permitted under applicable laws and regulations to receive the information contained herein and on the pages that follow, (3) you are either (a) located outside the United States and are not a US Person or (b) an existing shareholder of the Company who is a “qualified purchaser” as defined under the Investment Company Act and (4) you will not further transmit or send any information contained in this website to any other persons in the United States, to US Persons, or to any publications with a general circulation in the United States. If you cannot so represent, warrant, undertake and agree, you must click the button labelled “Decline” or otherwise exit this website.